Banking giant massively resets Jazz Pharma stock price target
View original at finance.yahoo.comBanking giant massively resets Jazz Pharma stock price target Changes in Wall Street price targets usually arrive in small increments. A few dollars up, a few dollars down, and sometimes a rating left untouched…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
UBS forecasts 10% revenue compound annual growth rate and 11% EPS compound annual growth rate for Jazz Pharmaceuticals from 2026 through 2030, ahead of consensus estimates of roughly 7% and 6% respectively
60% confidenceInvestors should pay more for each dollar of profit from Jazz Pharmaceuticals because growth looks more sustainable
60% confidenceJazz Pharmaceuticals deserves a multiple expansion from 7x to 10x earnings because growth looks more sustainable
60% confidenceJazz Pharmaceuticals is upgraded from Neutral to Buy, skipping the intermediate rating level
60% confidenceUBS projects approximately $3.1 billion in peak Ziihera sales driven by strong Phase 3 HERIZON-GEA data and projected 45% peak market penetration
60% confidencePrice target for Jazz Pharmaceuticals raised to $307 from $188
60% confidenceThe FDA Ziihera approval will drive a faster commercial ramp than the market currently assumes
60% confidence